ImmunityBio launches ANKTIVA commercially in Saudi Arabia for bladder and lung cancer
Updated
Updated · Simply Wall St · Apr 24
ImmunityBio launches ANKTIVA commercially in Saudi Arabia for bladder and lung cancer
9 articles · Updated · Simply Wall St · Apr 24
The Saudi launch has driven ImmunityBio shares up 12.97% over seven days, with the company now valued at US$8.3 billion and trading at US$8.19 per share.
Analysts see a potential fair value of $13.50 per share, citing rapid revenue growth, margin improvement, and AI-driven operations as key drivers, though future expansion depends on regulatory acceptance.
Despite recent momentum, ImmunityBio's five-year shareholder return remains negative, highlighting both opportunity and risk as the company pursues further international expansion and broader indications for ANKTIVA.
Is ImmunityBio stock a bargain, or does the FDA warning signal deeper problems?
Can ImmunityBio's AI strategy overcome its critical marketing and regulatory failures?
With insiders selling shares, how will the FDA's warning on misleading ads impact the company?
As ANKTIVA expands globally, can it escape the shadow of its U.S. regulatory issues?
Why was ANKTIVA approved for lung cancer in Saudi Arabia but not the United States?